106 Chapter 5 PMA: postmenstrual age A: Change in IGF-I in relation to change in weight SDS up to 36 weeks PMA. r 0.62 (95% CI 0.46 – 0.74, p < 0.001) B: Change in weight SDS from 30 weeks PMA onwards in relation to fat free mass and fat mass at term equivalent age. Partial correlation with fat free mass: r 0.72 (95% CI 0.56 – 0.82, p < 0.001) Partial correlation with fat mass: r 0.77 (95% CI 0.65 – 0.86, p < 0.001) (Correlations were controlled for gestational age at birth and postmenstrual age at time of body composition measurement) C: Change in weight SDS from 30 weeks PMA onwards in relation to fat free mass percentage at term equivalent age. Linear regression model: R²: 0.45 p < 0.001, B for change in weight SDS -54.0 (95% CI -72.0 − -35.9, p < 0.001) (gestational age at birth and postmenstrual age at the time of body composition measurement were entered in the regression model as covariates) IGF-I in relation to growth and body composition IGF-I levels are shown in figure 2. Between birth and term equivalent age IGF-I showed a mean (SD) increase of 0.4 (0.2) nmol/L per week. The change in IGF-I over time was independent of gestational age at birth (r – 0.07, 95% CI -0.27 – 0.16, p 0.608). The increase in IGF-I between birth and 36 weeks PMA positively correlated with the concurrent change in weight and head circumference SDS (respectively r 0.61, 95% CI 0.45 – 0.73, p < 0.001 and r 0.33, 95% CI 0.11 – 0.52, p 0.004), but not with the concurrent change in length SDS (r 0.20, 95% CI -0.02 – 0.41, p 0.081).
RkJQdWJsaXNoZXIy MTk4NDMw